Esteban Ribera

Summary

Affiliation: Hospital Universitari Vall d'Hebron
Country: Spain

Publications

  1. pmc Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort
    Vicente Estrada
    Hospital Clinico San Carlos, Madrid, Spain
    BMC Womens Health 11:36. 2011
  2. ncbi request reprint Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen
    Esteban Ribera
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Paseo Vall Hebron 119 129, 08035 Barcelona, Spain
    AIDS 20:1131-9. 2006
  3. pmc Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults
    Esteban Ribera
    Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d Hebron, Paseo Vall Hebron 119 129, 08035 Barcelona, Spain
    Antimicrob Agents Chemother 48:4256-62. 2004
  4. doi request reprint Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study)
    Esteban Ribera
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Barcelona, Spain
    HIV Clin Trials 9:407-17. 2008
  5. ncbi request reprint [Spanish recommendations for proper use of enfuvirtide]
    Esteban Ribera
    Hospital Vall d Hebron, Barcelona, Espana
    Enferm Infecc Microbiol Clin 25:131-42. 2007
  6. ncbi request reprint Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis
    Esteban Ribera
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Antimicrob Chemother 59:690-7. 2007
  7. ncbi request reprint Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients
    Esteban Ribera
    Infectious Diseases Service, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Antivir Ther 10:605-14. 2005
  8. doi request reprint [Clinical utility of atazanavir]
    Esteban Ribera Pascuet
    Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d Hebron, Barcelona, Espana
    Enferm Infecc Microbiol Clin 26:55-67. 2008
  9. ncbi request reprint Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study)
    Esteban Ribera
    Infectious Diseases Service, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Acquir Immune Defic Syndr 40:317-23. 2005
  10. doi request reprint Double-boosted protease inhibitor antiretroviral regimens: what role?
    Esteban Ribera
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Drugs 68:2257-67. 2008

Detail Information

Publications79

  1. pmc Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort
    Vicente Estrada
    Hospital Clinico San Carlos, Madrid, Spain
    BMC Womens Health 11:36. 2011
    ..The objective of the study is to describe the lipid profile in a large cohort of HIV-infected women on contemporary ART and analyse differences between regimes and patient's characteristics...
  2. ncbi request reprint Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen
    Esteban Ribera
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Paseo Vall Hebron 119 129, 08035 Barcelona, Spain
    AIDS 20:1131-9. 2006
    ..To assess the pharmacokinetics and tolerability of lopinavir (LPV), ritonavir (RTV) and atazanavir (ATV) as a double-boosted protease inhibitor regimen in HIV-infected adults...
  3. pmc Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults
    Esteban Ribera
    Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d Hebron, Paseo Vall Hebron 119 129, 08035 Barcelona, Spain
    Antimicrob Agents Chemother 48:4256-62. 2004
    ....
  4. doi request reprint Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study)
    Esteban Ribera
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Barcelona, Spain
    HIV Clin Trials 9:407-17. 2008
    ..Lipoatrophy is the most stigmatizing side effect of stavudine therapy. We assessed the long-term effects of replacing stavudine with tenofovir in HIV-infected patients with lipoatrophy...
  5. ncbi request reprint [Spanish recommendations for proper use of enfuvirtide]
    Esteban Ribera
    Hospital Vall d Hebron, Barcelona, Espana
    Enferm Infecc Microbiol Clin 25:131-42. 2007
    ....
  6. ncbi request reprint Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis
    Esteban Ribera
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Antimicrob Chemother 59:690-7. 2007
    ..To assess plasma steady-state pharmacokinetics (PK) of rifampicin, isoniazid, saquinavir and ritonavir in HIV and tuberculosis (TB) co-infected patients, and investigate potential interactions between TB drugs and protease inhibitors (PIs)...
  7. ncbi request reprint Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients
    Esteban Ribera
    Infectious Diseases Service, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Antivir Ther 10:605-14. 2005
    ..The purpose of this study was to evaluate the efficacy and safety of a once-daily regimen consisting of didanosine (ddI), lamivudine (3TC) and nevirapine (NVP) for adult antiretroviral-naive patients with HIV-1 infection...
  8. doi request reprint [Clinical utility of atazanavir]
    Esteban Ribera Pascuet
    Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d Hebron, Barcelona, Espana
    Enferm Infecc Microbiol Clin 26:55-67. 2008
    ....
  9. ncbi request reprint Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study)
    Esteban Ribera
    Infectious Diseases Service, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Acquir Immune Defic Syndr 40:317-23. 2005
    ....
  10. doi request reprint Double-boosted protease inhibitor antiretroviral regimens: what role?
    Esteban Ribera
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Drugs 68:2257-67. 2008
    ..The fixed combination of lopinavir/ritonavir tablets makes it easier to boost with another PI at the same time, without requiring ritonavir refrigeration, and this may be particularly useful in this setting...
  11. ncbi request reprint Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation?
    Esteve Ribera
    Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Enferm Infecc Microbiol Clin 23:41-67. 2005
    ....
  12. ncbi request reprint Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients
    Lluis Castells
    Liver Unit, Department of Medicine, Hospital Universitari Vail d Hebron, Barcelona, Spain
    Antivir Ther 11:1061-70. 2006
    ..To investigate the efficacy of early antiviral treatment for hepatitis C virus (HCV) recurrence in HIV/HCV-coinfected patients undergoing liver transplantation for end-stage liver disease...
  13. ncbi request reprint Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients
    Manuel Crespo
    Infectious Diseases Department, Hospital Universitari Vail d Hebron, Universitat Autonoma de Barcelona, Spain
    Antivir Ther 12:1217-23. 2007
    ..Therefore, it has been suggested that monitoring RBV serum levels could be used to drive dose modification and to optimize management of HCV-infected patients receiving combination treatment...
  14. doi request reprint Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study
    Josep Mallolas
    Hospital Clinic Universitari IDIBAPS, University of Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 51:29-36. 2009
    ..To evaluate the efficacy and safety of switching from boosted lopinavir (LPV/r) to boosted atazanavir (ATV/r) in virologically suppressed HIV-1-infected patients versus continuing LPV/r...
  15. doi request reprint Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial
    Adrian Curran
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Antivir Ther 17:711-8. 2012
    ....
  16. doi request reprint Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients
    Jose R Santos
    Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 27:713-7. 2011
    ....
  17. doi request reprint Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial
    Eva Van den Eynde
    Infectious Diseases Department, Vall d Hebron Hospital, Autonomous University of Barcelona, Spain
    Clin Infect Dis 48:1152-9. 2009
    ..To study the feasibility of a response-guided therapy for chronic hepatitis C virus (HCV) infection in patients coinfected with human immunodeficiency virus (HIV) in a tertiary care hospital...
  18. ncbi request reprint Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 7:163-71. 2006
    ..Regimens based on ritonavir-boosted protease inhibitors (PI/r) are often used as rescue interventions. It is unclear whether significant differences exist between distinct PI/r...
  19. ncbi request reprint Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    J Acquir Immune Defic Syndr 44:139-47. 2007
    ..To assess lipoatrophy, other toxicities, and efficacy associated with abacavir as compared with stavudine in HIV-infected antiretroviral-naive patients...
  20. doi request reprint Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy
    Adrian Curran
    Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Infectious Diseases Department, Spain
    AIDS 26:475-81. 2012
    ..To compare 48-week changes in body fat distribution and bone mineral density (BMD) between patients switching from a ritonavir-boosted protease inhibitor (PI/r) to raltegravir (RAL) and patients continuing with PI/r...
  21. doi request reprint Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort
    Manuel Crespo
    Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Antimicrob Chemother 63:189-96. 2009
    ..In an observational study, we analyse the efficacy and tolerability of didanosine plus lamivudine and efavirenz versus zidovudine plus lamivudine and efavirenz in a cohort of therapy naive patients...
  22. ncbi request reprint Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients
    Manuel Crespo
    Infectious Diseases Department, Spain
    AIDS 21:477-81. 2007
    ..To investigate the utility of a week-4 virological response for sustained response prediction in hepatitis C virus (HCV) genotype 3/HIV-co-infected patients treated with interferon and ribavirin for 24 weeks...
  23. doi request reprint Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz T
    Jose M Miro
    Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS Res Hum Retroviruses 26:747-57. 2010
    ..At 1 and 3 years, the immune reconstitution induced by an efavirenz-based regimen in very immunosuppressed patients was at least as potent as that induced by a ritonavir-boosted protease inhibitor-based antiretroviral regimen...
  24. ncbi request reprint Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients
    Esteban Martinez
    Hospital Clinic, Barcelona, Spain
    AIDS 21:367-9. 2007
    ..In contrast, abacavir showed a lower incidence of adverse effects leading to drug discontinuation...
  25. doi request reprint Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection
    Arkaitz Imaz
    Infectious Diseases Department, Hospital Universitari Vall d Hebron and Departament de Medicina, Universidad Autonoma de Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 52:382-6. 2009
    ..No data from clinical trials, about this combination, are available...
  26. ncbi request reprint Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study
    Lidia Ruiz
    Retrovirology Laboratory, IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Infect Dis 188:977-85. 2003
    ..66; 95% confidence interval, 0.47-0.93; P=.021). A prior STI seems to confer no additional benefit to subsequent virological or immunological outcomes of a salvage regimen...
  27. ncbi request reprint [Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia]
    Marta Martorell
    Unidad de Hemofilia, Servicio de Farmacia, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Enferm Infecc Microbiol Clin 23:349-52. 2005
    ..86 .g/ml (0.82-4.88 .g/ml) in patients with detectable viral load (p = 0.32). Nevirapine plasma concentrations were 4.41 .g/ml (3.50-6.72 .g/ml) and 3.12 .g/ml (2.44-3.80 .g/ml) respectively (p = 0.18)...
  28. ncbi request reprint Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine
    Cesar Fisac
    Nutrition Section, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Spain
    AIDS 19:917-25. 2005
    ..To evaluate the 24-month metabolic and morphological benefits obtained from replacing the protease inhibitor (PI) in a regimen with nevirapine, efavirenz or abacavir...
  29. pmc Ultrasensitive real-time PCR for the clinical management of visceral leishmaniasis in HIV-Infected patients
    Israel Molina
    Infectious Disease Department, Universitat Autonoma de Barcelona, Barcelona, Spain
    Am J Trop Med Hyg 89:105-10. 2013
    ..9%. Monitoring parasite load by an ultrasensitive quantitative Leishmania PCR is useful to predict the risk of relapse after a VL episode in HIV-infected patients...
  30. doi request reprint Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir
    Maria Saumoy
    Infectious Disease Service, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
    Antivir Ther 16:459-68. 2011
    ....
  31. ncbi request reprint Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Belvitge, L Hospitalet de Llobregat, Barcelona, Spain
    Curr HIV Res 10:673-8. 2012
    ..To describe the efficacy and tolerability of switching to raltegravir (RAL) in virologically suppressed HIV-1-infected patients during routine clinical practice...
  32. doi request reprint Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults
    Elena Ferrer
    HIV Unit, Service of Infectious Diseases, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Spain
    AIDS Res Hum Retroviruses 27:1061-5. 2011
    ..008) and subcutaneous fat (42%, p = 0.008). These data suggest that switching from LPV/r to ATV/r is associated with increased trunk fat, both subcutaneous and visceral...
  33. doi request reprint Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis
    Marylène Lejeune
    Immunology Service, Hospital Clinic Institut d Investigacions Biomèdiques Augustí Pi i Suñer, University of Barcelona, Barcelona, Spain
    Clin Infect Dis 52:662-70. 2011
    ..It is unknown whether a Toxoplasma gondii-specific T cell response is restored after successful combined antiretroviral therapy (cART) in patients with AIDS and current or previous toxoplasmic encephalitis (TE)...
  34. ncbi request reprint Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study
    Vicenc Falco
    Infectious Disease Department, Hospital Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    Vaccine 24:2567-74. 2006
    ..In conclusion, the immunogenicity conferred by the polysaccharide vaccine in HIV-infected patients under HAART is at least as good as that observed in healthy subjects...
  35. doi request reprint Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations
    Carolina Garrido
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 28:156-64. 2012
    ..001). Undetectable RAL C(t) was seen only in patients failing RAL without integrase resistance mutations (64.1% of them). RAL failures in the absence of integrase resistance mutations mainly reflect poor drug compliance...
  36. ncbi request reprint Management of tuberculosis in HIV-infected patients
    Adrian Curran
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    AIDS Rev 14:231-46. 2012
    ....
  37. ncbi request reprint Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART
    Manuel Crespo
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    Enferm Infecc Microbiol Clin 26:27-31. 2008
    ..The primary endpoint was median change in CD4+ T-cell counts at the end of treatment as compared to baseline. Secondary endpoints were safety and changes in the various T-cell subpopulations...
  38. ncbi request reprint Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study
    Hernando Knobel
    Department of Internal Medicine, Infectious Diseases, Hospital del Mar, Barcelona, Spain
    J Acquir Immune Defic Syndr 37:1276-81. 2004
    ..The use of antihistamines remains unclear in this setting. A double-blind placebo-controlled study was performed to evaluate the efficacy of cetirizine in the prevention of nevirapine rash...
  39. doi request reprint Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system
    Eva Van den Eynde
    Infectious Diseases Department, Vall d Hebron Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Antivir Ther 16:887-93. 2011
    ..Here, we studied the effect of abacavir, tenofovir or lamivudine addition on the suppressive activity of ribavirin in an HCV RNA replicon system...
  40. doi request reprint From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir
    Adrian Curran
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Institut de Recerca, Universitat Autonoma de Barcelona, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    Expert Opin Drug Saf 10:389-406. 2011
    ..Many studies have been performed replacing AZT or d4T with newer nucleoside analogs reverse transcriptase inhibitors (NRTIs) with less toxicity, such as tenofovir (TDF) or abacavir (ABC), maintaining virological efficacy...
  41. doi request reprint Bacterial meningitis in HIV-1-infected patients in the era of highly active antiretroviral therapy
    Pere Domingo
    Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    J Acquir Immune Defic Syndr 51:582-7. 2009
    ..The burden that spontaneous bacterial meningitis (SBM) currently represents among HIV-1-infected patients is poorly known...
  42. doi request reprint Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals
    Arkaitz Imaz
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Antimicrob Chemother 66:358-62. 2011
    ..The advent of new antiretrovirals has expanded the therapeutic options for multiple drug-resistant HIV-1 infection. The role of recycled nucleoside reverse transcriptase inhibitors (NRTIs) in this scenario remains uncertain...
  43. ncbi request reprint [Efficacy and safety of a reduced-dose of stavudine in HIV-infected patients under immunological and virological stable conditions]
    Enric Pedrol
    Unitat de Malalties Infeccioses VIH, Hospital General de Granollers, Granollers, Barcelona, Espana
    Med Clin (Barc) 129:361-5. 2007
    ..Stavudine (d4T) has shown a favourable short and long-term tolerability profile. Nevertheless, its usage is currently decreasing due to some safety concerns. We aimed to evaluate the efficacy and safety of d4T low-dose-based regimens...
  44. ncbi request reprint [Tuberculous meningitis: a comparative study in relation to concurrent human immunodeficiency virus infection]
    Carlos Azuaje
    Servicios de Enfermedades Infecciosas, Hospital Universitario Vall d Hebron, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    Enferm Infecc Microbiol Clin 24:245-50. 2006
    ..A comparative study was conducted between adult MT patients with and without concurrent human immunodeficiency virus (HIV) infection...
  45. doi request reprint Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients
    Adrian Curran
    Infectious Diseases Department, Hospital Vall d Hebron, Autonomous University of Barcelona, Barcelona, Spain
    J Antimicrob Chemother 65:2195-203. 2010
    ..To evaluate the virological efficacy, safety, tolerability and pharmacokinetics of a regimen containing 900/100 mg of ritonavir-boosted darunavir once daily in patients with antiretroviral experience but no darunavir resistance...
  46. doi request reprint Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality
    Miriam J Alvarez-Martinez
    Hospital Clinic IDIBAPS, Universitat de Barcelona, Barcelona, Spain
    Diagn Microbiol Infect Dis 62:34-43. 2008
    ..03 and P < 0.001, respectively). The prevalence of DHPS mutants in Spain is low and is not associated with a worse outcome. Severe respiratory failure at admission is the strongest predictor of PCP outcome...
  47. ncbi request reprint Leishmania infantum DNA detection in urine from patients with visceral leishmaniasis and after treatment control
    Roser Fisa
    Laboratory of Parasitology, Universitat de Barcelona, Barcelona, Spain
    Am J Trop Med Hyg 78:741-4. 2008
    ..This study suggests that urine-PCR is sensitive for diagnosis and may be useful to monitor treatment efficacy...
  48. ncbi request reprint Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial
    Jose M Miro
    Institut d Investigacions Biomediques August Pi Sunyer Hospital Clinic, University of Barcelona, Barcelona, Spain
    Clin Infect Dis 43:79-89. 2006
    ..To our knowledge, no randomized trials have evaluated whether prophylaxis against toxoplasmic encephalitis can be safely discontinued after the CD4+ T cell count increases in response to highly active antiretroviral therapy...
  49. doi request reprint The future of antiretroviral therapy: challenges and needs
    Santiago Moreno
    Department of Infectious Diseases, Hospital Ramon y Cajal, Carretera de Colmenar Km 9 100, 28034 Madrid, Spain
    J Antimicrob Chemother 65:827-35. 2010
    ..This document summarizes the group's conclusions on the future of antiretroviral treatment, presented as 20 relevant questions. Each question includes the current status of the topic and our vision for the future...
  50. ncbi request reprint Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less
    Elena Ferrer
    Infectious Disease Services, Universitari de Bellvitge Hospital, Barcelona, Spain
    AIDS 18:1727-9. 2004
    ..More than 80% of patients who continued with nevirapine had viral loads < 50 copies/ml and CD4 cell counts > 200 cells/pl...
  51. ncbi request reprint Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors
    Esteban Martinez
    Hospital Clinic IDIBAPS, Barcelona, Spain
    Antivir Ther 8:403-10. 2003
    ..Whether a therapeutic approach addressed to those metabolic abnormalities may have any impact on body fat is not clear...
  52. ncbi request reprint Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study
    Maria Penaranda
    Hospital Son Dureta, Barcelona, Spain
    Clin Infect Dis 45:e82-7. 2007
    ..Our objective was to determine the effectiveness of 23-valent PPV in HIV-infected adults and the risk factors for pneumococcal pneumonia or invasive pneumococcal disease...
  53. ncbi request reprint [Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study)]
    Pompeyo Viciana
    Servicio de Enfermedades Infecciosas, Hospital Virgen del Rocio, Sevilla, Spain
    Enferm Infecc Microbiol Clin 26:127-34. 2008
    ..The aim of this study, performed when QD regimens were still limited, was to determine the degree of adherence and patient satisfaction of QD dosing versus twice-daily dosing (BID) of ART...
  54. ncbi request reprint [Changing trends in HIV epidemics: recent diagnoses in the Spanish VACH cohort (2000-2002)]
    Ramon Teira
    Servicio de Enfermedades Infecciosas, Hospital de Basurto, Bilbao, Spain
    Enferm Infecc Microbiol Clin 23:213-7. 2005
    ..Studying the changing trends of HIV epidemics is a useful means of evaluating the results of current preventive plans as well as of defining future needs and objectives...
  55. pmc Association of thymidylate synthase polymorphisms with acute pancreatitis and/or peripheral neuropathy in HIV-infected patients on stavudine-based therapy
    Pere Domingo
    Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    PLoS ONE 8:e57347. 2013
    ..The use of d4T has been associated with acute pancreatitis and peripheral neuropathy. However, no relationship has ever been proved between TS polymorphisms and pancreatitis and/or peripheral neuropathy...
  56. doi request reprint HIV and TB coinfection: using adjusted doses of lopinavir/ritonavir with rifampin
    Adrian Curran
    Infectious Diseases Department, Hospital Universitari Vall de Hebrón, Universitat Autonoma de Barcelona, Passeig Vall de Hebron 119 129, 08035 Barcelona, Spain
    Expert Rev Anti Infect Ther 9:1115-8. 2011
    ..However, concerns arise regarding the real interactions, tolerability and virological efficacy in HIV-TB-coinfected patients, which may differ from healthy volunteers or HIV-infected patients without TB...
  57. ncbi request reprint Lactic acidosis related to nucleoside therapy in HIV-infected patients
    Vicenc Falco
    Infectious Diseases Division, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, P masculine Vall d Hebron 119 129 08035, Barcelona, Spain
    Expert Opin Pharmacother 4:1321-9. 2003
    ..Therapy is based on supportive measures and discontinuation of all antiretroviral drugs. Administration of essential vitamin coenzymes, electron acceptors and L-carnitine may be useful in some cases...
  58. ncbi request reprint Could mitochondrial DNA quantitation be a surrogate marker for drug mitochondrial toxicity?
    Carmen de Mendoza
    Service of Infectious Diseases, Department of Infectious Diseases, Hospital Carlos III, Spain
    AIDS Rev 6:169-80. 2004
    ..This review analyzes the current methods to determine mitochondrial damage and the available data to support their utility in clinical practice...
  59. ncbi request reprint Value of culture and nested polymerase chain reaction of blood in the prediction of relapses in patients co-infected with leishmania and human immunodeficiency virus
    Cristina Riera
    Laboratori de Parasitologia, Facultat de Farmacia, Universitat de Barcelona, Barcelona, Spain
    Am J Trop Med Hyg 73:1012-5. 2005
    ..However, the presence of viable parasites during post-treatment follow-up increased the probability of relapse and showed that culture positivity could be a good relapse marker...
  60. ncbi request reprint Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice
    Arkaitz Imaz
    HIV Unit, Infectious Diseases Department, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Spain
    AIDS Rev 13:180-93. 2011
    ....
  61. ncbi request reprint HIV infection late detection in AIDS patients of an European city with increased immigration since mid 1990s
    Dolors Carnicer-Pont
    Epidemiology Service of Public Health Agency of Barcelona, Lesseps 1, Barcelona, 08023, Spain
    Curr HIV Res 7:237-43. 2009
    ....
  62. doi request reprint Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Acquir Immune Defic Syndr 48:241-4. 2008
    ..Pure X4 and X4R5 dual-tropic viruses may be recognized in approximately 15% of drug-naive HIV-1-positive patients. CCR5 antagonists are active against R5 viruses; therefore, HIV tropism should be known before their prescription...
  63. doi request reprint Invasive pneumococcal disease in HIV-infected adults: clinical changes after the introduction of the pneumococcal conjugate vaccine in children
    Joaquin Burgos
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    J Acquir Immune Defic Syndr 59:31-8. 2012
    ..We conducted a multicenter study to analyze differences in clinical presentation of IPD between HIV-infected and non-HIV-infected adults in the prevaccine and postvaccine era...
  64. ncbi request reprint Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature
    Vicente Falco
    Infectious Diseases Division, Hospital Vall d Hebron, 08035 Barcelona, Spain
    Clin Infect Dis 34:838-46. 2002
    ..17; 95% CI, 0.04-0.73). We conclude that specific therapy with cofactors may improve the outcome for patients with this syndrome...
  65. ncbi request reprint Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study
    Fernando Laguna
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Instituto de Salud Carlos III, C Sinesio Delgado 12, 28029 Madrid, Spain
    J Antimicrob Chemother 52:464-8. 2003
    ..0006). The efficacy of ABLC is similar to meglumine antimoniate, but the severity of toxicity in the treatment of HIV-VL is lower with ABLC...
  66. ncbi request reprint Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy
    Queralt Jordano
    Infectious Disease Division, Hospital Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Infect Dis 38:1623-8. 2004
    ..Patients receiving trimethoprim-sulfamethoxazole (TMP-SMZ) were more likely to present with TMP-SMZ-resistant pneumococci than were those who were not receiving this agent (76.7% vs. 43.6%; P=.007). The mortality rate was high (21%)...
  67. doi request reprint [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR]
    Pere Domingo
    Unitat de Malalties Infeccioses, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Espana
    Enferm Infecc Microbiol Clin 31:20-9. 2013
    ..In summary, efficacy and safety data suggest that RPV plus 2 NRTI is an effective and safe initial antiretroviral regime...
  68. ncbi request reprint Liver transplantation in HIV-HCV coinfected patients: a case-control study
    Lluis Castells
    Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d Hebron, Universidad Autonoma de Barcelona, Barcelona, Spain
    Transplantation 83:354-8. 2007
    ..1%) of the control group and one patient (20%) of the HIV group presented a sustained virologic response (P=NS). Short- to midterm results of LT in HIV-HCV co-infected patients were excellent and similar to non-HIV patients...
  69. ncbi request reprint [Ventricular tachycardia and long QT associated with clarithromycin administration in a patient with HIV infection]
    Nuria Vallejo Camazón
    Servicios de Cardiología, Hospital General Vall d Hebron, Barcelona, Spain
    Rev Esp Cardiol 55:878-81. 2002
    ..We report a case of QT prolongation and development of ventricular arrhythmia in one HIV patient that started with intravenous clarithromycin and cotrimoxazole therapy...
  70. doi request reprint Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
    Juan Berenguer
    Hospital Gregorio Maranon, Madrid, Spain
    Clin Infect Dis 47:1083-92. 2008
    ..The combination of didanosine, lamivudine, and efavirenz (ddI/3TC/EFV) for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection has been insufficiently analyzed in clinical trials...
  71. ncbi request reprint Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen
    Cecilia Cabrera
    IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    AIDS 20:2075-80. 2006
    ..To analyse the genetic changes in the gp41 protein in HIV-infected patients with detectable plasma viraemia receiving a long-term salvage enfuvirtide regimen...
  72. ncbi request reprint Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment
    Andrew Hill
    Liverpool University, Liverpool, UK
    Expert Opin Pharmacother 8:679-88. 2007
    ....
  73. ncbi request reprint Hepatitis C virus and human immunodeficiency virus coinfection in Spain
    Bernardino Roca
    Hospital General, Castellon, Spain
    J Infect 47:117-24. 2003
    ....
  74. ncbi request reprint Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    N Engl J Med 349:1036-46. 2003
    ..We assessed the strategy of substituting nevirapine, efavirenz, or abacavir for a protease inhibitor in patients infected with human immunodeficiency virus type 1 (HIV-1) in whom virologic suppression had been achieved...
  75. doi request reprint First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort
    Pere Domingo
    Hospital de la Santa Creu i Sant Pau, Mas Casanovas 90, 08025 Barcelona, Spain
    J Antimicrob Chemother 61:1348-58. 2008
    ..A retrospective longitudinal study from the VACH cohort comparing both regimens was performed...
  76. ncbi request reprint Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2004 [correction]
    Juan Berenguer
    Unidad de Enfermedades Infecciosas, Hospital General Gregorio Maranon, Madrid, Spain
    Enferm Infecc Microbiol Clin 22:160-76. 2004
    ..To provide an update of guidelines from the Spanish AIDS Study Group (GESIDA) and the National AIDS Plan (PNS) committee on the prevention of opportunistic infections in adult and adolescent HIV-infected patients...
  77. ncbi request reprint Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis
    Jesus Oliva
    AIDS 17:637-8. 2003
  78. ncbi request reprint Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy
    Juan Berenguer
    Infectious Diseases Service of Hospital Gregorio Marañón, 28007, Madrid, Spain
    Clin Infect Dis 36:1047-52. 2003
    ..One-third of patients with PML died despite receipt of HAART; neurologic function improved in approximately one-half of the survivors. A CD4+ cell count of <100 cells/microL was associated with higher mortality...
  79. ncbi request reprint Epidemiological trends of HIV infection in Spain: preventative plans have to be oriented to new target populations (Spanish VACH Cohort)
    Ignacio Suarez-Lozano
    Hospital Infanta Elena, Huelva, Spain
    AIDS 16:2496-9. 2002